Categories
COVID-19 Industry Impact Education Health Latest Market Reports Law & Order Market Price Analysis Market Study Science/Astronomy U.S.

Allergic Rhino-Conjunctivitis Pipeline Insight 2020 By DelveInsight

(Albany, US) DelveInsight has launched a new report on Allergic Rhino-Conjunctivitis Pipeline

Allergic Rhino-Conjunctivitis Pipeline Insight, 2020” report by DelveInsight outlays comprehensive insights of present clinical development scenario and growth prospects across the Allergic Rhino-Conjunctivitis market. A detailed picture of the Allergic Rhino-Conjunctivitis pipeline landscape is provided, which includes the disease overview and Allergic Rhino-Conjunctivitis treatment guidelines. The assessment part of the report embraces in-depth Allergic Rhino-Conjunctivitis commercial assessment and clinical assessment of the Allergic Rhino-Conjunctivitis pipeline products from the pre-clinical developmental phase to the marketed phase. In the report, a detailed description of the drug is proffered including mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Allergic Rhino-Conjunctivitis collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.

Allergic Rhinoconjunctivitis (ARC), which is caused by an allergen, refers to nose and eye problems that occur at least once a week. When only the nose is affected, it is called allergic rhinitis (AR). It is also known as hay fever, “sinus” or “sensitive nose”. When only the eyes are affected, it is called allergic conjunctivitis. The disease is triggered by exposure to seasonal and/or perennial allergens and, depending on the nature of the allergenic triggers and patterns of exposure, symptoms may be persistent or intermittent.

Allergic Rhino-Conjunctivitis pipeline
                                       Allergic Rhino-Conjunctivitis pipeline

Request for free sample page:-  https://www.delveinsight.com/sample-request/allergic-rhino-conjunctivitis-pipeline-insight

Allergic Rhino-Conjunctivitis Pipeline

The development of new drugs for ARC is analyzed by highlighting the recent insights into the pathophysiological mechanisms of the disease. The major aim of development of drugs for ARC is to have agents able to prevent the inflammatory effects of the interaction between the allergen and the specific IgE antibodies on mast cell surface.

Some of the key players including LOFARMA S.P.A, Emergo Therapeutics, FAES Farma, and others are developing drugs for the treatment of Allergic Rhinoconjunctivitis. Lais allergoid tablets contain allergens that are modified by carbamylation. Due to their modified chemical structure, they are suitable for sublingual immunotherapy (SLIT). Based on their small molecule size of 12 to 40 kDa, they can be easily absorbed via the oral mucosa.

Norketotifen is the principal active metabolite of ketotifen, a known antagonist of the histamine H1 receptor and mast stabilizer. Ketotifen has been approved in over 95 countries worldwide, including the US and Europe, for the treatment of asthma and/or allergic conditions in children and adults. Norketotifen, however, has not been approved anywhere for any indication. Emergo has already completed all the scientific and commercial due diligence to reassure investors of the market potential for norketotifen in this lead indication. Recently the company completed the phase IIb clinical trial for ARC. Bilastine (a piperidine derivative), is a novel potent H1 antihistamine. It is at least as potent as cetirizine or fexofenadine in in vitro studies. In animal studies it demonstrates dose-dependent antihistaminic and anti-allergic effects. In humans its metabolism is not affected by age, gender or renal function but may be affected by co-administration of P glycoprotein inhibitors.

Marketed drug included in the report

  • Itulazax: ALK-Abelló A/S

Emerging drugs included in the report

  • Norketotifen: Emergo Therapeutics
  • LAIS Grass pollen tablets: LOFARMA S.P.A
  • Bilastine: FAES Farma

Allergic Rhino-Conjunctivitis Report Scope

  • The Allergic Rhino-Conjunctivitis report provides an overview of therapeutic pipeline activity and therapeutic assessment of the products by development stage, product type, route of administration, molecule type, and MOA type for Allergic Rhino-Conjunctivitis across the complete product development cycle, including all clinical and nonclinical stages.
  • It comprises of detailed profiles of Allergic Rhino-Conjunctivitis therapeutic products with key coverage of developmental activities, including technology, collaborations, licensing, mergers and acquisition, funding, designations and other product-related details
  • Detailed Allergic Rhino-Conjunctivitis research and development progress and trial details, results wherever available, are also included in the pipeline study.
  • Coverage of dormant and discontinued pipeline projects along with the reasons if available across Allergic Rhino-Conjunctivitis.

Download free sample page:-  https://www.delveinsight.com/sample-request/allergic-rhino-conjunctivitis-pipeline-insight

Table of content

1. Report Introduction

2. Allergic Rhino-Conjunctivitis

3. Allergic Rhino-Conjunctivitis Current Treatment Patterns

4. Allergic Rhino-Conjunctivitis – DelveInsight’s Analytical Perspective

5. Therapeutic Assessment

6. Allergic Rhino-Conjunctivitis Late Stage Products (Phase-III)

7. Allergic Rhino-Conjunctivitis Mid Stage Products (Phase-II)

8. Early Stage Products (Phase-I)

9. Pre-clinical Products and Discovery Stage Products

10. Inactive Products

11. Dormant Products

12. Allergic Rhino-Conjunctivitis Discontinued Products

13. Allergic Rhino-Conjunctivitis Product Profiles

14. Allergic Rhino-Conjunctivitis Key Companies

15. Allergic Rhino-Conjunctivitis Key Products

16. Dormant and Discontinued Products

17. Allergic Rhino-Conjunctivitis Unmet Needs

18. Allergic Rhino-Conjunctivitis Future Perspectives

19. Allergic Rhino-Conjunctivitis Analyst Review

20. Appendix

21. Report Methodology

Related Reports

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions

Contact Us

Shruti Thakur

[email protected]

+91-9650213330

Categories
COVID-19 Industry Impact Education Health Latest Market Reports Law & Order Market Price Analysis Market Study Science/Astronomy U.S.

Allergic Rhino-Conjunctivitis Epidemiology Forecast to 2030 By DelveInsight

(Albany, US) DelveInsight has launched a new report on Allergic Rhino-Conjunctivitis Epidemiology

DelveInsight’s ‘Allergic Rhino-Conjunctivitis Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Allergic Rhino-Conjunctivitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Allergic Rhinoconjunctivitis (ARC), which is caused by an allergen, refers to nose and eye problems that occur at least once a week. When only the nose is affected, it is called allergic rhinitis (AR). It is also known as hay fever, “sinus” or “sensitive nose”. When only the eyes are affected, it is called allergic conjunctivitis. The disease is triggered by exposure to seasonal and/or perennial allergens and, depending on the nature of the allergenic triggers and patterns of exposure, symptoms may be persistent or intermittent.

Allergic Rhino-Conjunctivitis epidemiology
                                               Allergic Rhino-Conjunctivitis epidemiology

Request for free sample page:-  https://www.delveinsight.com/sample-request/allergic-rhino-conjunctivitis-epidemiology-forecast

Allergic Rhino-Conjunctivitis Epidemiology

Allergic rhinoconjunctivitis (ARC) is a common chronic disorder in children. It can cause learning problems and has a great impact on quality of life. Uncontrolled allergic may aggravate the symptoms of asthma. The term allergic rhinoconjunctivitis is preferable to allergic rhinitis because most patients also have ocular symptoms. Individuals generally develop symptoms of AR or ARC before the age of 20 years, with approximately 40% of patients becoming symptomatic by 6 years of age. Approximately 50–60% of patients with allergic rhinitis have associated symptoms of allergic conjunctivitis that on total constitutes the cases of ARC.

Allergic rhinoconjunctivitis Key Facts

  • The study conducted by Blaiss et al., titled “The burden of allergic rhinitis and allergic rhinoconjunctivitis on adolescents”, estimates that in an European analysis of population-based studies the estimated prevalence was found to be 15.1–37.8% in adolescents aged 12–15 years, and data from a cross-sectional study in the US estimated an AR prevalence of 24.8% in 14–17 year. It was also observed that prevalence in this age group is increasing.
  • According to the study conducted by Langen et al., titled “Prevalence of allergic diseases in Germany: results of the German Health Interview and Examination Survey for Adults (DEGS1)”, the lifetime prevalence of allergic rhinoconjunctivitis was found to be 14.8%.
  • The High Prevalence Of Allergic Rhinoconjunctivitis And Correlation With Cedar And Cypress Pollen Counts In Japanese Schoolchildren” conducted by Yoshida et al., in Japan, the prevalence of ARC is 16.2% in younger children (6–7 years) and 21.7% in older children (13–14 years). There was a positive correlation between the prevalence of ARC and the cedar pollen counts in younger children.
  • Allergic Rhinoconjunctivitis: Epidemiology”, estimates that the prevalence of reported rhinitis with itchy, watery eyes (rhinoconjunctivitis) varied among centers from 0.8% to 14.9% in the 6–7-year-olds and from 1.4% to 39.7% in the 13–14-year-olds. In the United States, the ISAAC surveys found the prevalence to range from 12% to 22% among the 13–14-year-olds.

Allergic rhinoconjunctivitis Report Scope 

  • The Allergic Rhino-Conjunctivitis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Allergic Rhino-Conjunctivitis Epidemiology Report and Model provide an overview of the risk factors and global trends of Allergic Rhino-Conjunctivitis in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Allergic Rhino-Conjunctivitis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Allergic Rhino-Conjunctivitis
  • The report provides the segmentation of the Allergic Rhino-Conjunctivitis epidemiology

Download free sample page:- https://www.delveinsight.com/sample-request/allergic-rhino-conjunctivitis-epidemiology-forecast

Table of content

1. Key Insights

2. Executive Summary of Allergic Rhino-Conjunctivitis

3. Allergic Rhino-Conjunctivitis: Disease Background and Overview

4. Patient Journey

5. Epidemiology and Patient Population

6. Treatment Algorithm, Current Treatment, and Medical Practices

7. KOL Views

8. Unmet Needs

9.  Appendix

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

Why should you buy this report?

  • The Allergic Rhino-Conjunctivitis Epidemiology report will allow the user to –
  • Develop business strategies by understanding the trends shaping and driving the global Allergic Rhino-Conjunctivitis market
  • Quantify patient populations in the global Allergic Rhino-Conjunctivitis market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Allergic Rhino-Conjunctivitis therapeutics in each of the markets covered
  • Understand the magnitude of Allergic Rhino-Conjunctivitis population by its epidemiology
  • The Allergic Rhino-Conjunctivitis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources.

Related Reports

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions

Contact Us

Shruti Thakur

[email protected]

+91-9650213330

Categories
COVID-19 Industry Impact Education Health Latest Market Reports Law & Order Market Price Analysis Market Study Science/Astronomy U.S.

Allergic Rhino-Conjunctivitis Market Insights By DelveInsight

(Albany, US) DelveInsight has launched a new report on Allergic Rhino-Conjunctivitis Market

DelveInsight’s “Allergic Rhino-Conjunctivitis Market Insights, Epidemiology, and Market Forecast-2030″ report delivers an in-depth understanding of the Allergic Rhino-Conjunctivitis, historical and forecasted epidemiology as well as the Allergic Rhino-Conjunctivitis market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan. The Allergic Rhino-Conjunctivitis market report provides current treatment practices, emerging drugs, Allergic Rhino-Conjunctivitis market share of the individual therapies, current and forecasted Allergic Rhino-Conjunctivitis market Size from 2017 to 2030 segmented by seven major markets. The Report also covers current Allergic Rhino-Conjunctivitis treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses the underlying potential of the market.

Allergic Rhinoconjunctivitis (ARC), which is caused by an allergen, refers to nose and eye problems that occur at least once a week. When only the nose is affected, it is called allergic rhinitis (AR). It is also known as hay fever, “sinus” or “sensitive nose”. When only the eyes are affected, it is called allergic conjunctivitis. The disease is triggered by exposure to seasonal and/or perennial allergens and, depending on the nature of the allergenic triggers and patterns of exposure, symptoms may be persistent or intermittent.

Allergic Rhino-Conjunctivitis market
                                                  Allergic Rhino-Conjunctivitis market

Request for free sample page:-  https://www.delveinsight.com/sample-request/allergic-rhinoconjunctivitis-market

Allergic Rhino-Conjunctivitis Treatment

The most important allergens involved in allergic rhinoconjunctivitis in children include indoor allergens (present throughout the year, such as house dust mite and pet allergens) and outdoor allergens (seasonal, such as pollen from grass and trees). Food allergens do not cause allergic rhinoconjunctivitis. Like most allergies, treatment of ARC consist of allergen avoidance and the use of medications.

Antihistamines are safe and effective even in very young children. Topical steroids such as nasal sprays are also safe options. As they require a longer time to work, they need to be used regularly over days to weeks to reap the benefits. They are particularly helpful in reducing nasal blockage or congestion. Among the mentioned therapies, intranasal glucocorticosteriods are the most effective treatment of allergic rhinoconjunctivitis in adults. They reduce nose and eye symptoms and the use of other drugs, and they improve overall daily functioning. They are more effective than antihistamines. Second generation H1 antihistamines are effective and safe for treating allergic rhinoconjunctivitis in children.

Management of allergic conjunctivitis consists of basic eye care, avoidance of allergy triggers, and over-the-counter and prescription topical and systemic therapies, as well as allergen immunotherapy. The most common treatment options for allergic conjunctivitis consist of topical ophthalmic formulations intended to reduce inflammation and provide symptomatic relief. This includes an antihistamine, a decongestant, a nonsteroidal anti-inflammatory drug (NSAID), or a mast cell stabilizer. Some drops contain a combination of these. Some eye drops require a prescription. Surgical intervention may be indicated in severe cases. Oral antihistamines for allergic conjunctivitis are cetirizine, fexofenadine, and loratadine. These are usually taken once a day. Antihistamine eye drops include Alaway and Zaditor. The eye drops will relieve symptoms in the eyes, but the oral dose will also help treat a runny nose and other symptoms. The most commonly prescribed antihistamine eye drops include azelastine, emedastine, and ketotifen. They are applied to the eyes two or three times a day. Mast cell stabilizers are generally well tolerated, however, as they can take 3–7 days to show an effect, they are commonly used to prevent symptoms before they occur and can be used as long as necessary

Allergic Rhino-Conjunctivitis Market Insight

Most children with allergic conjunctivitis have allergic rhinitis. Ocular symptoms are common and contribute to the burden of allergic rhinitis and lower quality of life. Ocular allergies rank a very close second and at times may overcome the primary complaints of nasal congestion in rhinoconjunctivitis patients. Allergic rhinitis may be seasonal (a condition commonly referred to as hay fever) or perennial.

The seasonal form is caused by allergens released during tree, grass, or weed pollination, whereas the perennial form is caused by allergies to animal dander, dust mites, or mold spores with or without associated pollinosis. Because of the non–life-threatening nature of symptoms, AR and ARC have, in the past, been considered trivial diseases but are increasingly recognized as having a major effect on quality of life (QOL), emotional well-being, sleep, daily activities, and productivity when poorly controlled. The problem of uncontrolled rhinitis, despite treatment, continues to represent a therapeutic challenge in some patients.

Allergic Rhino-Conjunctivitis Report Scope

  • The report covers the descriptive overview of Allergic Rhino-Conjunctivitis, explaining its causes, signs and symptoms, pathophysiology, diagnosis and currently available therapies
  • Comprehensive insight has been provided into the Allergic Rhino-Conjunctivitis epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Allergic Rhino-Conjunctivitis are provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of Allergic Rhino-Conjunctivitis market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Allergic Rhino-Conjunctivitis market

Download free sample page:- https://www.delveinsight.com/sample-request/allergic-rhinoconjunctivitis-market

Table of content

1. Key Insights

2. Executive Summary of Allergic Rhino-Conjunctivitis

3. Competitive Intelligence Analysis for Allergic Rhino-Conjunctivitis

4. Allergic Rhino-Conjunctivitis: Market Overview at a Glance

5. Allergic Rhino-Conjunctivitis: Disease Background and Overview

6. Patient Journey

7. Allergic Rhino-Conjunctivitis Epidemiology and Patient Population

8. Treatment Algorithm, Current Treatment, and Medical Practices

9. Unmet Needs

10. Key Endpoints of Allergic Rhino-Conjunctivitis Treatment

11. Marketed Products

12. Emerging Therapies

13. Allergic Rhino-Conjunctivitis: Seven Major Market Analysis

14. Attribute analysis

15. 7MM: Market Outlook

16. Access and Reimbursement Overview of Allergic Rhino-Conjunctivitis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Why should you buy this report?

  • The report will help in developing business strategies by understanding trends shaping and driving the Allergic Rhino-Conjunctivitis market
  • To understand the future market competition in the Allergic Rhino-Conjunctivitis market and Insightful review of the key market drivers and barriers
  • Organize sales and marketing efforts by identifying the best opportunities for Allergic Rhino-Conjunctivitis in the US, Europe (Germany, Spain, Italy, France, and the United Kingdom) and Japan
  • Identification of strong upcoming players in the market will help in devising strategies that will help in getting ahead of competitors
  • Organize sales and marketing efforts by identifying the best opportunities for Allergic Rhino-Conjunctivitis market
  • To understand the future market competition in the Allergic Rhino-Conjunctivitis market.

Related Reports

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for life science vertical and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions

Contact Us

Shruti Thakur

[email protected]

+91-9650213330

Categories
Health

Allergic Rhino Conjunctivitis Epidemiology Forecast

DelveInsight’s ‘Allergic Rhino-Conjunctivitis – Epidemiology Forecast to 2030‘ report delivers an in-depth understanding of the disease, historical and forecasted Allergic Rhino-Conjunctivitis epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period2017-2030

Allergic Rhino-Conjunctivitis Understanding

The DelveInsight Allergic Rhino-Conjunctivitis epidemiology report gives a thorough understanding of the Allergic Rhino-Conjunctivitis by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for Allergic Rhino-Conjunctivitis in the US, Europe, and Japan. The report covers the detailed information of the Allergic Rhino-Conjunctivitis epidemiology scenario in seven major countries (US, EU5, and Japan).

Allergic Rhino-Conjunctivitis Epidemiology Perspective by DelveInsight

The Allergic Rhino-Conjunctivitis epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The Allergic Rhino-Conjunctivitis epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The Allergic Rhino-Conjunctivitis epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

Allergic Rhino-Conjunctivitis Detailed Epidemiology Segmentation

The Allergic Rhino-Conjunctivitis epidemiology covered in the report provides historical as well as forecasted Allergic Rhino-Conjunctivitis epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight Allergic Rhino-Conjunctivitis report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report

  • The Allergic Rhino-Conjunctivitis report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The Allergic Rhino-Conjunctivitis Epidemiology Report and Model provide an overview of the risk factors and global trends of Allergic Rhino-Conjunctivitis in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of Allergic Rhino-Conjunctivitis in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of Allergic Rhino-Conjunctivitis
  • The report provides the segmentation of the Allergic Rhino-Conjunctivitis epidemiology

Report Highlights

  • 11-Year Forecast of Allergic Rhino-Conjunctivitis epidemiology
  • 7MM Coverage
  • Total Cases of Allergic Rhino-Conjunctivitis
  • Total Cases of Allergic Rhino-Conjunctivitis according to segmentation
  • Diagnosed cases of Allergic Rhino-Conjunctivitis

KOL- Views

We interview, KOLs and SME’s opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Request for sample pages

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to Allergic Rhino-Conjunctivitis?
  • What are the key findings pertaining to the Allergic Rhino-Conjunctivitis epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of Allergic Rhino-Conjunctivitis across the 7MM during the forecast period (2017-2030)?
  •  Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the Allergic Rhino-Conjunctivitis?
  • What are the currently available treatments of Allergic Rhino-Conjunctivitis?

Reasons to buy

  • The Allergic Rhino-Conjunctivitis Epidemiology report will allow the user to –
  • Develop business strategies by understanding the trends shaping and driving the global Allergic Rhino-Conjunctivitis market
  • Quantify patient populations in the global Allergic Rhino-Conjunctivitis market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for Allergic Rhino-Conjunctivitis therapeutics in each of the markets covered
  • Understand the magnitude of Allergic Rhino-Conjunctivitis population by its epidemiology
  • The Allergic Rhino-Conjunctivitis Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of contents

1. Key Insights

2. Executive Summary of Allergic Rhino-Conjunctivitis

3. Allergic Rhino-Conjunctivitis: Disease Background and Overview

3.1. Introduction

3.2. Sign and Symptoms

3.3. Pathophysiology

3.4. Risk Factors

3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Allergic Rhino-Conjunctivitis Epidemiology Scenario in the 7MM (2017- 2030)

5.4. United States Epidemiology

5.4.1. Allergic Rhino-Conjunctivitis Epidemiology Scenario in the United States (2017- 2030)

5.5. EU-5 Country-wise Epidemiology

5.5.1. Germany Epidemiology

5.5.1.1. Allergic Rhino-Conjunctivitis Epidemiology Scenario in Germany (2017- 2030)

5.5.2. France Epidemiology

5.5.2.1. Allergic Rhino-Conjunctivitis Epidemiology Scenario in France (2017- 2030)

5.5.3. Italy Epidemiology

5.5.3.1. Allergic Rhino-Conjunctivitis Epidemiology Scenario in Italy (2017- 2030)

5.5.4. Spain Epidemiology

5.5.4.1. Allergic Rhino-Conjunctivitis Epidemiology Scenario in Spain (2017- 2030)

5.5.5. United Kingdom Epidemiology

5.5.5.1. Allergic Rhino-Conjunctivitis Epidemiology Scenario in the United Kingdom (2017-2030)

5.6. Japan Epidemiology

5.6.1. Allergic Rhino-Conjunctivitis Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

6.1. Allergic Rhino-Conjunctivitis Treatment and Management

6.2. Allergic Rhino-Conjunctivitis Treatment Algorithm

7. KOL Views

8. Unmet Needs

9.  Appendix

9.1. Bibliography

9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight